Advancing Obesity Research Through Neurocircuitry Mapping & CNS Engagement
Ace Therapeutics is a preclinical contract research organization dedicated to providing comprehensive services for obesity research. Recognizing the complex neurobiological factors underlying obesity, we offer specialized neurocircuitry mapping and central nervous system (CNS) engagement services to accelerate the development of innovative anti-obesity therapies.
Obesity is increasingly understood as a condition involving the dysregulation of central neurocircuits that govern appetite, metabolism, and energy balance. The brain's intricate network plays a vital role in maintaining energy homeostasis. Disruptions within these circuits can contribute to the development and persistence of obesity.
Neurocircuitry mapping allows for the detailed investigation of neural pathways involved in appetite, satiety, energy expenditure, and reward-driven eating behaviors. By elucidating these neural substrates, researchers can gain a more precise understanding of the mechanisms contributing to obesity.
Fig.1. Obesity is associated with abnormality of fronto-mesolimbic circuitry and impaired cognitive functions. (Li, G., et al. 2023)
Partnering with Ace Therapeutics provides access to experienced neuroscientists with a deep understanding of the neurobiological mechanisms of obesity. We utilize advanced technologies in neuroimaging, electrophysiology, and molecular biology to deliver high-quality neurocircuitry mapping and CNS engagement data. We offer customized preclinical study designs tailored to your specific research questions. Our services include in-depth analysis and expert interpretation of complex neurocircuitry and CNS engagement data, providing valuable insights into the mechanism of action of your therapeutic candidates.
High-resolution mass spectrometry and in situ perfusion models quantify compound distribution across murine and non-human primate BBB.
Autoradiography and positron emission tomography (PET) imaging validate target binding kinetics in obesity-relevant brain regions.
Electrophysiological recordings and c-Fos activation mapping correlate drug exposure with neural activity patterns.
Automated home-cage monitoring systems track real-time changes in feeding cycles, locomotor activity, and metabolic parameters.
| Brain Region | Key Neurotransmitters/Peptides Involved | Role in Obesity |
| Hypothalamus | Leptin, Ghrelin, Neuropeptide Y, GLP-1 | Appetite regulation, satiety signaling, energy balance |
| Brainstem | GLP-1, other gut peptides | Satiety signaling, relay of peripheral signals to higher brain regions |
| Reward Pathways | Dopamine, Endocannabinoids, Opioids | Hedonic aspects of eating, motivation for food, reward-driven eating |
| Prefrontal Cortex | Dopamine, Serotonin | Cognitive control of food intake, inhibitory processes related to eating |
| Arcuate Nucleus | Leptin, Insulin, Ghrelin, AgRP, POMC | Central integration of metabolic signals, primary site of action for many hormones |
Neurocircuitry mapping and CNS engagement have diverse applications in preclinical obesity research:
Unlock the potential of neurocircuitry mapping and CNS engagement for your preclinical obesity research. Contact Ace Therapeutics today to learn more about our services and how we can help you advance your drug discovery pipeline.
Reference
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics is a preclinical research leader specializing in obesity and metabolic disorders, offering validated models and advanced analytics to accelerate anti-obesity drug development. With a decade of expertise, we deliver end-to-end solutions, empowering biopharma innovators to transform therapies from concept to preclinical success.